Padrões de tratamento de pacientes com câncer de mama metastático após falha de antraciclina e taxano sob a perspectiva do sistema público de saúde brasileiro
Padrões de tratamento de pacientes com câncer de mama metastático após falha de antraciclina e taxano sob a perspectiva do sistema público de saúde brasileiro
Tipo de documento
Apresentação
Descrição
Resumo apresentado na The Professional Society for Health Economics and Outcomes Research (ISPOR)
Fonte
ISPOR
Ano de publicação
2009
Referência (Vancouver)
Serrano SV, Nita M, Teich V, Litalien G, Teich N, Rached R, Donato BM, Rahal E. Treatment patterns of patients with metastatic breast cancer after failure to anthracycline and taxane under the Brazilian public health care system perspective [Internet]. In: ISPOR Latin America 2009; Rio de Janeiro, Brazil. Disponível em: https\://www\.ispor.org/heor-resources/presentations-database/presentation/ispor-2nd-latin-america-conference/treatment-patterns-of-patients-with-metastatic-breast-cancer-after-failure-to-anthracycline-and-taxane-under-the-brazilian-public-health-care-system-perspective
Treatment Patterns of Patients with Metastatic Breast Cancer After Failure to Anthracycline and Taxane Under the Brazilian Public Health Care System Perspective
Document type
Presentation
Description
Abstract presented at The Professional Society for Health Economics and Outcomes Research (ISPOR)
Source
ISPOR
Publication year
2009
Reference (Vancouver)
Serrano SV, Nita M, Teich V, Litalien G, Teich N, Rached R, Donato BM, Rahal E. Treatment patterns of patients with metastatic breast cancer after failure to anthracycline and taxane under the Brazilian public health care system perspective [Internet]. In: ISPOR Latin America 2009; Rio de Janeiro, Brazil. Available from: https\://www\.ispor.org/heor-resources/presentations-database/presentation/ispor-2nd-latin-america-conference/treatment-patterns-of-patients-with-metastatic-breast-cancer-after-failure-to-anthracycline-and-taxane-under-the-brazilian-public-health-care-system-perspective
Objetives Identificar os padrões atuais de tratamento para pacientes com câncer de mama metastático (CBM), refratário a antraciclinas e taxanos, tratados sob a perspectiva do sistema público de saúde Brasileiro. Methods Um estudo transversal de pacientes de 4 hospitais públicos nas regiões sul e sudeste do Brasil. Todos os pacientes ≥18 anos diagnosticados com CBM que progrediram após tratamento com antraciclinas e taxanos entre 2003 e 2006, com pelo menos 4 meses de sobrevida após a doença metastática, foram incluídos. Os dados foram coletados dos prontuários médicos. Results Foram incluídos na análise 217 pacientes com idade média de 52 anos (25-80 anos). Entre os pacientes com teste HER2 (59%), 40% eram HER-2 positivos e entre os pacientes com teste de receptor hormonal (89%), 51% eram positivos para receptor hormonal. 85% dos pacientes tinham informações sobre os tratamentos recebidos em seus prontuários médicos. Os regimes de quimioterapia mais frequentemente prescritos após o uso de antraciclinas e taxanos ("primeira linha") foram capecitabina (52,7%), gemcitabina+cisplatina (17,4%) e tamoxifeno (8,7%). O tratamento de segunda linha foi prescrito para 58% dos pacientes: gemcitabina+cisplatina (23,4%), capecitabina (20,6%), vinorelbina (14,0%), tamoxifeno (12,1%), paclitaxel (4,7%) e letrozol (4,7%). A mediana de regimes de tratamento foi 2, variando de 1 a 6. A utilização média de recursos por paciente/ano incluiu 1,85 radiografias simples de tórax, 0,57 tomografias de tórax, 1,06 ultrassonografias abdominais, 0,46 tomografias abdominais e 0,86 cintilografias ósseas. A sobrevida média dos pacientes após o primeiro diagnóstico de câncer de mama foi de 44,8 meses (DP: 35,8; mediana: 32,0) e após o primeiro diagnóstico de metástase foi de 22,4 meses (DP: 20,0; mediana: 16,1). A sobrevida média após a progressão para antraciclinas e taxanos foi de 12,7 meses (DP: 12,4; mediana: 8,4).
Notas
O registro foi originalmente publicado em inglês. A versão em português foi traduzida com o apoio de inteligência artificial.
Abstract
Objetives: To identify current treatment patterns of care for patients with metastatic breast cancer (MBC), refractory to anthracyclines and taxanes, treated under the perspective of the Brazilian public health care system. Methods A cross-sectional study of patients from 4 public hospitals in south and southeast region of Brazil. All patients ≥18 years diagnosed with MBC who had progressed following treatment with an anthracycline and a taxane between 2003 and 2006, with at least 4 months of survival after metastatics disease were included. Data was collected from their medical charts. Results 217 patients with an average age of 52 years (25-80 years old) were included in the analysis. Among patients with HER2 testing (59%), 40% were HER-2 positive and among patients with hormone receptor testing (89%), 51% were hormone receptor positive. 85% of the patients had information regarding treatments received in their medical charts. The most frequent chemotherapy regimens prescribed following use of anthracycline and taxane ("first line") were capecitabine (52.7%), gemcitabine+cisplatin (17.4%), and tamoxifen (8.7%). Second line treatment was prescribed for 58% of patients: gemcitabine+cisplatin (23.4%), capecitabine (20.6%), vinorelbine (14.0%), tamoxifen (12.1%), paclitaxel (4.7%) and letrozol (4.7%). The median number of treatment regimens was 2, with a range of 1 to 6. The average resources utilization per patient/year included 1.85 plain thorax x-rays, 0.57 thorax CTs, 1.06 abdominal ultra-sounds, 0.46 abdominal CTs and 0.86 bone scintigraphies. The average survival of patients after first breast cancer diagnosis was 44.8 months (SD: 35.8; median: 32.0) and after first diagnosis of metastasis was 22.4 months (SD: 20.0; median: 16.1). The average survival post progression to anthracyclines and taxanes was 12.7 months (SD: 12.4; median: 8.4). Conclusions Within the Brazilian public health care system, the most frequently used first and second line treatments, for MBC.
Notes
The record was originally published in English. The Portuguese version was translated with the aid of artificial intelligence.
